AIM ImmunoTech Announces Publication Of Phase 1 Data From Roswell Park Study On Ampligen In Early-Stage Triple-Negative Breast Cancer In The Journal For ImmunoTherapy Of Cancer
AIM ImmunoTech Announces Publication Of Phase 1 Data From Roswell Park Study On Ampligen In Early-Stage Triple-Negative Breast Cancer In The Journal For ImmunoTherapy Of Cancer
aim immunotech宣布罗斯韦尔公园研究关于早期三阴性乳腺癌中阿米芬使用的1期数据在《癌症免疫疗法杂志》上发表
AIM ImmunoTech Announces Publication Of Phase 1 Data From Roswell Park Study On Ampligen In Early-Stage Triple-Negative Breast Cancer In The Journal For ImmunoTherapy Of Cancer
aim immunotech宣布罗斯韦尔公园研究关于早期三阴性乳腺癌中阿米芬使用的1期数据在《癌症免疫疗法杂志》上发表